{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "16433472",
  "DateCompleted": {
    "Year": "2006",
    "Month": "02",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2016",
    "Month": "11",
    "Day": "24"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1053-0894",
      "JournalIssue": {
        "Volume": "16",
        "Issue": "1",
        "PubDate": {
          "Year": "2006",
          "Month": "Jan"
        }
      },
      "Title": "The AIDS reader",
      "ISOAbbreviation": "AIDS Read"
    },
    "ArticleTitle": "Adverse reactions associated with dapsone therapy in HIV-positive patients: a case presentation and review.",
    "Pagination": {
      "StartPage": "47",
      "EndPage": "55",
      "MedlinePgn": "47-8, 53-5; discussion 54-5"
    },
    "Abstract": {
      "AbstractText": [
        "Dapsone is commonly used for the prophylaxis of Pneumocystis jiroveci pneumonia in patients with a diagnosis of HIV infection who have allergies to sulfa-based drugs. Dapsone has several adverse effects in its profile that make it a potentially dangerous second-line agent. We report an adverse effect encountered in an HIV-positive patient receiving dapsone and review the common adverse effects encountered with this alternative treatment option."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Oklahoma College of Pharmacy, Tulsa, USA."
          }
        ],
        "LastName": "Stroup",
        "ForeName": "Jeffrey S",
        "Initials": "JS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Stephens",
        "ForeName": "Johnny R",
        "Initials": "JR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Reust",
        "ForeName": "Randall",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Miller",
        "ForeName": "J Angela",
        "Initials": "JA"
      }
    ],
    "PublicationTypeList": [
      "Case Reports",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "AIDS Read",
    "NlmUniqueID": "9206753",
    "ISSNLinking": "1053-0894"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "8W5C518302",
      "NameOfSubstance": "Dapsone"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "AIDS-Related Opportunistic Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Dapsone"
    },
    {
      "QualifierName": [
        "physiopathology"
      ],
      "DescriptorName": "Drug Hypersensitivity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "Pneumocystis carinii"
    },
    {
      "QualifierName": [
        "etiology",
        "prevention & control"
      ],
      "DescriptorName": "Pneumonia, Pneumocystis"
    }
  ]
}